VITRAKVI
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI (larotrectinib) capsules, for oral use VITRAKVI (larotrectinib) oral solution Initial U.S. Approval: 2018
0c8ca614-58b2-4aa4-83d3-0387a8f782fd
HUMAN PRESCRIPTION DRUG LABEL
Nov 3, 2023
Bayer HealthCare Pharmaceuticals Inc.
DUNS: 005436809
Products 4
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
LAROTRECTINIB
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (7)
LAROTRECTINIB
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (12)
LAROTRECTINIB
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (3)
LAROTRECTINIB
Product Details
FDA regulatory identification and product classification information